Business Wire

Helical Fusion Achieves Milestone Toward Commercial Fusion Energy, Advancing to Integrated Demonstration Device

Share

— World’s First Performance Test of a High-Temperature Superconducting Coil Under Conditions Replicating the Magnetic Environment Inside a Fusion Device —

Helical Fusion Co., Ltd., a world-leading developer of the Helical Stellarator, has completed a critical performance test of a high-temperature superconducting (HTS) coil—a core component of commercial fusion reactors. The company has now commenced manufacturing and construction of its integrated demonstration device, Helix HARUKA.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251026597002/en/

Helical Fusion members celebrating the successful HTS test with an “HTS Graduation!” sign and graduation caps

Watch the key points of this release in a 2-minute video: https://youtu.be/UhgQHfKtvow

Helical Fusion is the only company in the world building upon expertise in the Helical Stellarator approach, accumulated for more than 60 years at national institutes and national universities, which has been proven to possess the optimal characteristics for commercial power generation. As the sole inheritor of this knowledge from the National Institute for Fusion Science (NIFS), Helical Fusion is driving the Helix Program to realize the world’s first commercially viable fusion power plant using the Helical Stellarator.

Under the Helix Program, the company aims to complete performance tests of its two key technologies—HTS magnets and the integrated blanket/divertor system—by the end of the 2020s. By the 2030s, Helical Fusion plans to achieve full system integration through Helix HARUKA and begin steady-state power generation with its fusion pilot plant, Helix KANATA.

About the Performance Test

Significance

This milestone marks the world's first successful demonstration of an HTS coil constructed with a fully-functional large-scale conductor:

  1. The coil is based on a conductor cable designed for commercial fusion power plants' scale use 1
  2. The test replicated the magnetic environment inside a fusion device 2, including both self-generated and external magnetic fields
  3. Successfully conducted a current test under superconducting conditions

Using NIFS’s unique large-diameter, high-field testing facility, the conductor achieved stable superconducting current flow at 40 kA under a 7-tesla external magnetic field at 15 K (-258°C).

This result establishes Helical Fusion as one of the world’s leading contenders in the race toward commercial fusion energy and meets the technical threshold required to advance to the integrated demonstration device, Helix HARUKA.

Strong Collaboration with the National Laboratory and the Government

Since its founding in 2021, Helical Fusion has worked closely with NIFS through multiple joint research initiatives. In March 2024, a dedicated joint research team and lab space were established at NIFS to accelerate the development of HTS magnets and blanket/divertor systems - a model of Japan’s public-private partnership in fusion innovation.

The company’s progress is supported by Japan’s SBIR Phase 3 program, the first national grant scheme dedicated to fusion energy under the Ministry of Education, Culture, Sports, Science and Technology (MEXT). The establishment of this program was strongly initiated by Ms. Sanae Takaichi, the current Prime Minister of Japan, during her tenure as Minister for the Cabinet Office, where she championed the inclusion of fusion energy as a national strategic priority. Helical Fusion received the program’s largest amount, JPY 2 billion (≒USD 13 million).

Importance of HTS Magnet Development

Fusion reactors require magnetic fields strong enough to confine plasma exceeding 100 million degrees Celsius. For commercial plants, these fields must be generated efficiently and compactly — a challenge that makes HTS technology indispensable.

While many companies produce HTS materials, only a few possess the capability to design and engineer full-scale superconducting systems for real reactor environments. Helical Fusion’s success demonstrates its technical leadership in this domain.

About the Helix Program

The Helix Program targets the launch of the world’s first commercially viable fusion power plant in the 2030s through its Fusion Pilot Plant, Helix KANATA. The program defines three essential requirements for commercially viable fusion power:

  1. Steady-state operation: 24/7/365 stable performance
  2. Net electricity output: generating more energy than it consumes
  3. Maintainability: regular, efficient component maintenance

Out of more than 50 fusion development projects worldwide—spanning tokamak and laser-based approaches—the Helical Stellarator is uniquely capable of meeting all three criteria with existing technologies. The Helix Program aims to be the world’s first initiative to realize all of these requirements by the 2030s.

Powered by a strong partnership with NIFS and supported by Japan's world-class manufacturing industry, Helical Fusion is committed to leading the global fusion energy sector—a market expected to reach trillions of dollars in scale in the coming decades.

Comment from Co-Founder, CEO Takaya Taguchi

This achievement is undoubtedly a remarkable laboratory milestone born from Japan’s strong collaboration between industry, government, and academia.

Yet, more importantly, it marks a global turning point — a moment when everyone pursuing or believing in commercial fusion must recognize Helical Fusion as one of the most promising contenders for realization.

I am immensely proud of our joint team with the National Institute for Fusion Science (NIFS) — the giant of fusion research from which our company originated — and deeply grateful to our Japanese manufacturing partners whose craftsmanship made this success possible.

As we move forward to the next stage, we invite the world to watch closely and share in the excitement of what comes next.

Comment from Co-Founder, CTO Junichi Miyazawa

The development of high-temperature superconducting (HTS) magnets marks a powerful shift from laboratory research to real-world implementation.

Over years of dedicated work, the global fusion community has advanced material and magnet technologies that did not even exist when I began our research — technologies that now give us strong confidence in achieving commercial fusion power.

This successful test is the culmination of many years of development and close collaboration with partners across academia and industry. We will channel our deepest gratitude into the continued progress of Helix HARUKA and Helix KANATA.

About Helical Fusion Co., Ltd.

Helical Fusion is a Japan-based startup developing the world’s first commercially viable net power fusion plant, leveraging the expertise of the Helical Stellarator and inheriting more than 60 years of national fusion research.

Helical Fusion has raised JPY 5.2 billion (≈USD 34 million) to date and targets commercial operation in the 2030s under its “Helix Program”.

 ___________________________________

1 This coil is made using advanced high-temperature superconducting (HTS) technology, and it was constructed without electrical insulation. Among all HTS coil technologies, this marks the world’s first successful test of uninsulated a large-scale HTS conductor-based coil.

2 “the magnetic environment inside a fusion device” refers to a setting in which external magnetic fields—separate from those generated by the coil itself—are present, creating complex electromagnetic interactions between multiple currents through the magnetic field. In future fusion power plants, such environments are expected to include intense radiation, neutron flux, and even stronger magnetic fields.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251026597002/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Colorectal, Liver, and Lung Cancer Patients at Vinmec Experience Extended Survival with AIET Cell-Based Immunotherapy – Technology Transferred from Japan27.10.2025 07:39:00 CET | Press release

Vinmec Health System attracts international patients to Vietnam for treatment Significantly extended survival and improved quality of life (QoL) for cancer patients achieved through autologous cell-based AIET immunotherapy, utilizing patients' own natural killer (NK) cells and T cells, has positioned Vinmec Hospital, Vietnam, as an emerging medical tourism destination for cancer treatment across Asian countries. This accomplishment was presented by Professor Nguyen Thanh Liem at the NCRM NICHE 2025. He acknowledged the technology transfer support from GN Corporation, Japan, enabling the implementation of standardized AIET protocols in accordance with Japanese regulations, bringing treatment access to patients at Vinmec since 2018. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251026088789/en/ Professor Nguyen Thanh Liem, Director, Institute of Stem Cell and Genetic Technology Research at Vinmec International Hospital, Hanoi

METI will hold GGX Finance Summit27.10.2025 07:30:00 CET | Press release

On November 5 (Wed), the Ministry of Economy, Trade and Industry (METI) will hold the GGX Finance Summit at The Capitol Hotel Tokyu and on-line. In order to further develop discussions on transition finance, industry decarbonization, and other topics related to how business and finance contribute to decarbonization, we will promote mutual cooperation between the government, business, and financial sectors, and hold discussions to lead the international rule-making process to achieve both emission reductions and economic growth. Outline of GGX Finance Summit Date: November 5th, 2025 10:00-16:45 (JST, GMT+9:00) Venue: The Capitol Hotel Tokyu (Tokyo) (2-10-3, Nagata-cho, Chiyoda-ku, Tokyo 100-0014, Japan) Organizer: Ministry of Economy, Trade and Industry (METI), GX Acceleration Agency Co-organizer: World Business Council for Sustainable Development (WBCSD), TCFD Consortium Format: Hybrid (On-site and on-line) Language: Japanese/English (with English/Japanese simultaneous interpretation)

NITMX, Ant International and Krungthai Bank Expand Payment Connectivity Between Thailand and China via PromptPay27.10.2025 04:37:00 CET | Press release

The parties will promote inbound payments via PromptPay and Alipay, an Alipay+ e-wallet partner, enabling more convenience for Chinese travellersPartnership builds on Alipay+’s efforts to support the tourism industry in Thailand and enable local merchants to connect with travellers from China and beyond Under the guidance of the Bank of Thailand, Ant International, a leading global digital payment, digitisation and financial technology provider and National ITMX will partner to enhance and promote payments connectivity via PromptPay, between Thai merchants and Chinese consumers, which will be launched soon. Krungthai Bank will be the settlement bank for this cross-border QR partnership. In the initial phase, Chinese travellers to Thailand can use Alipay, an Alipay+ e-wallet partner, to make QR payment at millions of local merchants by scanning the PromptPay QR. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251026429360/en/

Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura® (Ruxolitinib Cream) in Adults with Moderate Atopic Dermatitis26.10.2025 01:55:00 CEST | Press release

Eight-week results from the TRuE-AD4 trial demonstrate treatment with Opzelura® (ruxolitinib cream) significantly improved the clinical signs of atopic dermatitis (AD), including improved itch as early as Day 2, and was well tolerated in adults with moderate AD who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) At Week 8, 70% of patients treated with Opzelura achieved a ≥75% improvement in the Eczema Area and Severity Index (EASI75) and 61.3% achieved Investigator’s Global Assessment Treatment Success (IGA-TS), co-primary endpoints of the study Based on these results, Incyte expects to file a Type-II variation application for ruxolitinib cream 1.5% for the treatment of adults with moderate AD in the European Union (EU) by end of year Incyte (Nasdaq:INCY) today announced new data from the Phase 3b TRuE-AD4 study evaluating the efficacy and safety of Opzelura® (ruxolitinib cream) in adults with moder

MultiBank Group and Khabib Nurmagomedov Launch an Exclusive Worldwide Multi-Billion-Dollar Joint Venture to Build the World’s First Regulated Tokenized Sports Ecosystem25.10.2025 10:24:00 CEST | Press release

MultiBank Group, the world’s largest financial derivatives institution, has entered into an exclusive worldwide multi-billion-dollar joint venture with global sports icon and undefeated UFC champion Khabib Nurmagomedov (29-0) to create a first-of-its-kind regulated ecosystem connecting global finance, sports and technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251025540563/en/ MultiBank Group and Khabib Nurmagomedov Launch an Exclusive Worldwide Multi-Billion-Dollar Joint Venture to Build the World’s First Regulated Tokenized Sports Ecosystem The partnership will culminate in the creation of a multi-billion-dollar joint venture, MultiBank Khabib LLC, uniting two global powerhouses: MultiBank Group, a leader in regulated financial excellence, and Khabib Nurmagomedov, undefeated in the octagon and whose influence extends far beyond sport.The company will operate from MultiBank Group’s headquarters in Dubai, building

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye